Abstract:Background: Concurrent chemoradiotherapy now represents the standard of care in locally advanced unresectable squamous cell carcinoma of the head and neck, and the administration of cisplatin in triweekly or weekly schedules is the most commonly used chemotherapeutic agent. However, the chemotherapeutic agent and its scheduling with radiation is still an area of investigation with safer toxicity profile and better response rates. Gemcitabine is a potent radiosensitizer, and non-cytotoxic concentration results in decreased systemic toxicity while maintaining radiosensitization properties. Furthermore, data are emerging for low-dose and long-duration infusion where this strategy is found to be effective and a safe alternative to standard brief infusion. Based on these two strategies, that is, non-cytotoxic concentration with long duration, we have explored the unique possibility of further lowering the toxicity profile without compromising the efficacy. Method: Eligible patients of locally advanced unresectable squamous cell carcinoma of the head and neck underwent radiation treatment with concurrent gemcitabine. A total dose of 70 Gy in 35 fractions over a period of seven weeks with conventional fractionation schedule was delivered with cord off after 44 Gy. Concurrent gemcitabine was administered intravenously for over two hours once a week, 1-2 h before radiation and for seven consecutive weeks at 50 mg/m2. Result: Fifty-two patients was enrolled in this study, out of which 41 completed the treatment. Fifty-nine percent completed treatment within seven weeks. Sixty-four percent were found to have received more than five cycles. Mean follow-up of patients was found to be 4.9 months. Sixty-eight percent had complete response. Stage III patients achieved more complete response compared to stage IV. There was no site-wise difference in achieving complete response. Patients who have received less than five chemo cycles or completed the treatment in more than seven weeks had less complete response. Sixty-one percent had severe mucositis while 39% developed mild/moderate mucositis. Considering skin toxicity, 80% were found to have mild/moderate skin toxicity, while only 20% suffered from severe grades of skin toxicity. Conclusion: Gemcitabine in low-dose and long-duration infusion is a potent radiosensitizer with safer hematological toxicity and manageable local toxicities.

Analysis of Chemotherapy with 5-Fu by Continous Intravenous Infusion Combind with Cisplatin in Patients with Advanced Squamous Cell Carcinoma of the Head and Neck

Analysis of chemotherapy with 5-FU by continous intravenous infusion and cisplatin in head and neck advanced cancer

Continuous Infusion of 5-FU with Split-Dose Cisplatin: an Effective Treatment for Advanced Squamous-Cell Carcinoma of the Head and Neck.

Advances in Nonsurgical Treatment of Head and Neck Squamous Cell Carcinoma

Efficacy of Oxaliplatin Combined with Pirarubicin and 5-Fluorouracil for Advanced Hepatocellular Carcinoma

[Experience of gemcitabine plus cisplatin chemotherapy in 52 patients with head and neck cancer].

Neoadjuvant Dose-Modified Docetaxel in Squamous Cell Carcinoma of the Head and Neck: A Phase 3 Study

Chronomodulated Chemotherapy of Oxaliplatin Combined 5-FU and CF Plus Levamisole on Colorectal Cancer of 41 Cases

[The Use of Two-Route Cisplatin Chemotherapy in the Treatment of Oral Squamous Cell Carcinoma].

[Clinical Analysis of Nimotuzumab Plus Cisplatin and Fluorouracil Regimen As Induction Treatment in Resectable Head and Neck Squamous Cell Carcinoma].

Platinum-Based Chemotherapy Plus Cetuximab First-Line for Asian Patients with Recurrent And/Or Metastatic Squamous Cell Carcinoma of the Head and Neck: Results of an Open-Label, Single-Arm, Multicenter Trial

Efficacy of Brachytherapy Concomitant with Chemotherapy with Docetaxel, Cisplatin, and 5-Fluorouracil in Unresectable Head and Neck Squamous Cell Carcinoma.

Clinical Effect of Iodine 125 Seeds Implantation Synchronized Chemotherapy with Docetaxel, ;Cisplatin,5-Fluorouracil for Unresectable Head and Neck Squamous Cell Carcinoma

Navelbine Combined with Cisplatin,leucovorin and 5-Fluorouracil for Advanced Esophageal Carcinoma

Concurrent chemoradiation with low-dose and long-duration weekly infusion of gemcitabine in unresectable squamous cell carcinoma of head and neck (SCCHN)

Combined Taxane, Platinum, and Cetuximab As a First‐line Treatment for Recurrent/metastatic Head and Neck Squamous Cell Carcinoma: Retrospective Study

Efficacy and safety of systemic treatments for patients with recurrent/metastatic head and neck squamous cell carcinoma: A systematic review and network meta-analysis

Treatment of Advanced and Metastatic Colorectal Cancer with Combined Chemotherapy Based on Oxaliplatin, Irinotecan and Fluorouracil

High Intensity Focused Ultrasound in Combination with Chemotherapy: A Clinical Study for Advanced Malignancy of Digestive System

Tolerability, Efficacy and Feasibility of Concurrent Gemcitabine and Cisplatin (CGP) Combined With Intensity Modulated Radiotherapy for Loco-Regionally Advanced Carcinoma of the Cervix

Phase I Dose-Escalating Study of 24-H Continuous Infusion of 5-Fluorouracil in Combination with Weekly Docetaxel and Cisplatin in Patients with Advanced Gastric Cancer.